Form 4: Curis Inc. CEO Granted Stock Options Following Shareholder Approval
SEC Form 4 Filing
James E. Dentzer, President & CEO of Curis Inc., reports the acquisition of stock options following shareholder approval of an amendment to the company's stock incentive plan.
Summary
- James E. Dentzer, the President and CEO of Curis Inc., was granted employee stock options on May 20, 2025.
- The options, representing the right to buy 360,000 shares of Curis Inc. common stock at an exercise price of $3.13, were granted following shareholder approval of Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan.
- The grant was contingent upon this shareholder approval, which occurred at the 2025 annual meeting of shareholders.
- The options vest as to 25% of the original shares on January 28, 2026, and then an additional 6.25% each quarter until January 28, 2029.
- The expiration date for the options is January 27, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. The shareholder approval indicates support for the company's compensation strategy.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The vesting schedule is typical for such grants.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Vesting schedules of 3-4 years are common, aligning with industry norms for incentivizing long-term performance.
- Comparable companies often use similar equity-based compensation to attract and retain talent.
Stakeholder Impact
- Shareholders may view the option grant as a positive sign, aligning management's interests with their own.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| January 28, 2025 | Board of Directors approved the option grant contingent upon shareholder approval. |
| May 20, 2025 | Date of earliest transaction; shareholder approval of Amendment No. 1 to the Fifth Amended and Restated 2010 Plan at the 2025 annual meeting. |
| May 22, 2025 | Date of Form 4 filing. |
| January 28, 2026 | First vesting date for 25% of the options. |
| January 28, 2029 | Final vesting date for the options. |
| January 27, 2035 | Expiration date of the options. |
Keywords
stock options, Curis Inc., CEO, James E. Dentzer, shareholder approval, stock incentive plan, Form 4, CRIS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.